Fidelis Capital Partners LLC Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fidelis Capital Partners LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 447 shares of the biopharmaceutical company’s stock after selling 54 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $298,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of REGN. LGT Fund Management Co Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 23.9% during the fourth quarter. LGT Fund Management Co Ltd. now owns 560 shares of the biopharmaceutical company’s stock worth $399,000 after buying an additional 108 shares during the period. Plato Investment Management Ltd raised its stake in Regeneron Pharmaceuticals by 1.7% during the 4th quarter. Plato Investment Management Ltd now owns 2,661 shares of the biopharmaceutical company’s stock valued at $1,902,000 after acquiring an additional 44 shares during the last quarter. Bellecapital International Ltd. lifted its position in Regeneron Pharmaceuticals by 44.1% during the 4th quarter. Bellecapital International Ltd. now owns 19,600 shares of the biopharmaceutical company’s stock worth $13,962,000 after acquiring an additional 6,002 shares during the period. SBI Securities Co. Ltd. purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $464,000. Finally, Jones Financial Companies Lllp increased its holdings in shares of Regeneron Pharmaceuticals by 107.7% in the fourth quarter. Jones Financial Companies Lllp now owns 812 shares of the biopharmaceutical company’s stock valued at $578,000 after purchasing an additional 421 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Citigroup lowered their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Robert W. Baird cut their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $675.49 on Wednesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The company has a market capitalization of $73.85 billion, a price-to-earnings ratio of 17.65, a PEG ratio of 2.34 and a beta of 0.08. The stock has a fifty day moving average of $697.13 and a two-hundred day moving average of $859.13. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $11.86 EPS. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.